why choose us

First received: October 08, 2022

Clinical Trial: Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population

Study Status: Completed

Recruit Status: RECRUITING

Condition: Herpes Zoster

Study Type: INTERVENTIONAL


Official Title: Phase 1/2 Open-label Trial of Safety and Zoster Immunogenicity Evaluation for People With HIV With CD4 Counts Under and Above 300 Following Shingrix Vaccination and Healthy Volunteers (ZEUS)

Brief Summary: Background:Shingles is a painful, blistering rash caused by the same virus that causes chickenpox.Shingrix is a vaccine approved to prevent shingles in healthy adults over age 50 and in immunocompromised adults over age 18.Researchers want to learn more about how people with HIV respond to Shingrix.Objective:To learn how Shingrix affects the immune response in people with HIV.Eligibility:People aged 18 years and older with HIV.Healthy people aged 50 years or older are also needed.Design:Participants will have at…

Read more